TRANSGENE news, videos and press releases
For more news please use our advanced search feature.
TRANSGENE - More news...
TRANSGENE - More news...
- Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
- Transgene Announces Financial Calendar for 2025
- Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024
- Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
- Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
- Availability of Transgene’s Half-Year Financial Report as of June 30, 2024
- Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
- 2024 Half-Year Financial Report
- Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
- Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
- Transgene to Participate in HTID Conference and Investor Access Forum in Paris
- Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC
- Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
- Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2024
- Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
- Transgene’s Combined General Meeting of May 15, 2024
- Availability of Transgene's 2023 Universal Registration Document
- Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
- Transgene Announces Upcoming Investor Meetings
- Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
- Transgene Announces Financial Calendar for 2024
- Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
- Transgene Receives $15.3 Million from the Sale of Securities Held for Sale
- Transgene: Balance Sheet of the Liquidity Contract with Natixis Oddo BHF SCA as of June 30, 2023
- Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
- Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023
- Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors
- Transgene provides business update and Q1 2023 financial position
- Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer
